Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.10.0.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 1,614 $ 7,522
Restricted cash 361 361
Receivables 189 65
Inventory 1,317 0
Contract assets 291 0
Prepaid expenses and other current assets 421 362
Total current assets 4,193 8,310
Property and equipment, net 424 595
Total assets 4,617 8,905
Current liabilities:    
Accounts payable 575 821
Accrued clinical trials expenses 474 289
Other accrued liabilities 401 354
Deferred revenue 939 0
Current portion of long-term debt 0 3,000
Total current liabilities 2,389 4,464
Long-term debt, net of discount 3,541 3,584
Total liabilities 5,930 8,048
Commitments and contingencies
Stockholders' equity (deficit):    
Common stock, at amounts paid-in 297,855 297,855
Additional paid-in capital 27,577 26,273
Accumulated deficit (326,745) (323,271)
Total stockholders' equity (deficit) (1,313) 857
Total liabilities and stockholders' equity (deficit) $ 4,617 $ 8,905